Access Pharmaceuticals Announces Poster Presentations on ProLindacat the American Association for Cancer Research 2007 Annual Meeting
DALLAS, April 16, 2007 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. announced today that results of studies of the mechanism of ProLindac's anticancer activity will be presented today at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles at the Los Angeles Convention Center. The two poster presentations describe preclinical studies performed by Access collaborators at two prominent institutes in France.
"We are delighted to have two ProLindac poster presentations at one of the most prestigious scientific conferences in cancer," stated David P. Nowotnik, Access' Senior Vice President, Research and Development. "The presentations reaffirm ProLindac's potential to become a leading cancer treatment. The posters focus on how ProLindac can be delivered in much higher doses than current therapies and shows its potential for superior efficacy, given alone as well as in combination with other anticancer compounds. Access has successfully completed a Phase 1 clinical study indicating at least five times more platinum could be administered to patients with ProLindac than oxaliplatin before the onset of toxicity. We are currently studying ProLindac in a Phase 2 monotherapy trial, treating patients with relapsed ovarian cancer."
The first poster is entitled "Antiproliferative effects of ProLindac, a novel DACH-platinum linked polymer-compound, compared to oxaliplatin and cisplatin in a panel of human cancer cell lines." This poster describes studies which examine ProLindac's cytotoxic effects either as single agent or in combination with other cytotoxics, and molecular mechanisms of action of ProLindac in comparison to oxaliplatin and cisplatin in a panel of human cancer cell lines. Results of the study indicated ProLindac and oxaliplatin showed similar cytotoxicity profiles when used in combination with either Gemcitabine, Docetaxel, 5-FU or SN38 (a camptothecin analog). This provides an early indication that ProLindac can effectively substitute for oxaliplatin in combination therapies. While this study shows that ProLindac and oxaliplatin have similar cytotoxicities on an equimolar basis, in vivo studies reported elsewhere demonstrate that much higher doses of ProLindac can be administered compared to oxaliplatin. Therefore, based on the data presented here, ProLindac has potential for superior efficacy in vivo. This work was conducted primarily at the Department of Medical Oncology, Hospital Beaujon, Clichy, France.
The second poster is entitled "Preclinical study of the transport and intracellular distribution of ProLindac, a novel diaminocyclohexane-platinum (DACH-Pt) tumor-targeting drug delivery system." This poster describes studies which examine the transportation and distribution of ProLindac in human cancer cell lines and the rate of formation of -platinum-DNA-adducts. It is the formation of such adducts which appears to be a major contributor to the anticancer activity of platinum drugs. High levels of these adducts are formed when tumor cells are exposed to ProLindac. Incubation of tumor cells with ProLindac resulted in an increase in G2/M phase and apoptosis in human cancer cell lines. Both of these effects are associated with antitumor activity. Intracellular concentrations of platinum in HCT-116 tumor cells were about 10-fold greater when the incubating medium pH was lowered from 7.0 to 5.4. Previously Access had shown a faster release of platinum as pH is lowered in a simple aqueous system. This study confirms that tumor cell uptake of platinum from ProLindac is enhanced as pH is lowered; lowered pH is typically seen in hypoxic tumors. This work was conducted primarily at the Rene Huguenin Cancer Center, Saint-Cloud, France.
Access' lead compound, ProLindac(TM), is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. The Company believes that ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed DACH platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and one in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer in 2007.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.
CONTACT: Stephen B. Thompson, Vice President and Chief Financial Officerof Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations,Donald C. Weinberger, or media, Alisa Steinberg, both of Wolfe AxelrodWeinberger Assoc. LLC, +1-212-370-4500; or Andrew Hellman of CEOcast, Inc.,+1-212-732-4300, all for Access Pharmaceuticals, Inc.
Posted: April 2007